

# The different radiosensitivity when combining erlotinib with radiation at different administration schedules might be related to activity variations in c-MET-PI3K-AKT signal transduction

Hong-Qing Zhuang<sup>1,\*</sup>

Qi-Fu Bo<sup>2,\*</sup>

Zhi-Yong Yuan<sup>1</sup>

Jun Wang<sup>1</sup>

Lu-Jun Zhao<sup>1</sup>

Ping Wang<sup>1</sup>

<sup>1</sup>Department of Radiotherapy, Tianjin Cancer Institute and Hospital, Tianjin Key Laboratory of Cancer Prevention and Therapy, and Tianjin Lung Cancer Center, Tianjin, People's Republic of China; <sup>2</sup>Department of Anatomy, Weifang Medical University, Weifang, Shandong Province, People's Republic of China

\*These authors contributed equally to this work

**Objectives:** The aim of this paper was to investigate the efficacy and activity variation associated with phosphoinositide 3-kinase (PI3K) signal transduction when combining erlotinib with radiation, using different administration schedules.

**Materials and methods:** Erlotinib was delivered to A973 cancer cells in the following three ways: (1) irradiation after administration, (2) irradiation upon administration, and, (3) irradiation before administration. The cell-survival rates were detected using colony-forming assays, while cell apoptosis was detected with flow cytometry. The expression levels of C-MET, p-C-MET, AKT, and p-AKT were determined via Western blotting analysis, under 6 Gy irradiation with/without erlotinib.

**Results:** The sensitizer enhancement ratios (SERs) of erlotinib irradiation after administration, irradiation upon administration, and irradiation before administration groups were 2.19, 1.53, and 1.38, respectively. A higher apoptosis rate was observed when irradiation was delivered after erlotinib. In addition, changes in cell apoptosis were found to be related to concurrent changes in C-MET, p-C-MET, AKT, and p-AKT expression. Protein expression increased in the combination groups, with trends showing a negative relationship with cell apoptosis.

**Conclusion:** The radiosensitive effect of erlotinib varied because of the different administration schedules; this variation may be related to PI3K signal transduction and its associated regulating effect.

**Keywords:** tyrosine kinase inhibitor, radiosensitization effects, erlotinib, PI3K

## Introduction

Epidermal growth factor receptor (EGFR) is an important target in tumor therapy,<sup>1-7</sup> and EGFR tyrosine kinase inhibitors (TKIs) have shown antitumor activities in non-small cell lung cancer patients.<sup>8,9</sup> When EGFR TKIs are used concurrently with radiotherapy, their potential effects may increase. However, the optimal administration schedule for combining TKIs with radiotherapy is unclear, and the mechanism of TKIs also warrants further research. This study investigated the different radiosensitization effects of TKIs and their relationship to C-MET-phosphoinositide 3-kinase (PI3K)-AKT signal transduction expression at different drug administration times, in A973 cells. The findings of this study provide support for the potential improvement in the therapeutic effect when TKI is combined with radiotherapy.

Correspondence: Hong-Qing Zhuang  
Department of Radiotherapy, Tianjin  
Cancer Institute and Hospital,  
Tianjin, People's Republic of China  
Tel +86 22 2334 1405  
Fax +86 22 2334 1405  
Email hongqingzhuang@163.com

## Material and methods

### Reagents

Roswell Park Memorial Institute (RPMI) 1640 cell culture medium (Gibco, Carlsbad, CA, USA) was provided by Hangzhou Sijiqing Biological Engineering Materials Co, Ltd (Hangzhou, People's Republic of China). Primary antibodies against C-MET and phosphorylated C-MET (p-C-MET), as well as against AKT and phosphorylated AKT (p-AKT), were obtained from Santa Cruz Biotechnology Inc (Dallas, TX, USA). Secondary antibody, horse radish peroxidase (HRP)-labeled goat anti-mouse IgG, was obtained from Jackson Laboratories, Inc. (West Grove, PA, USA). Erlotinib (a TKI) was generously provided by F Hoffman-La Roche Ltd (Basel, Switzerland); Annexin V and propidium iodide (PI) were purchased from Cell Signaling Technology, Inc (Beverly, MA, USA).

### Cell culture and ionizing radiation treatment

The A973 lung cancer cell line (Peking University, Beijing, People's Republic of China)<sup>10,11</sup> was maintained in 10% heat-inactivated fetal bovine serum (Amresco LLC, Solon, OH, USA) and RPMI 1640 medium supplemented with 4 mM glutamine, 100 mg/mL streptomycin, 100 IU/mL penicillin, and 20 mM hydroxyethyl piperazineethanesulfonic acid (HEPES) (Amresco LLC), in a humid atmosphere consisting of 5% CO<sub>2</sub> and 95% air, at 37°C. In a tissue-culture flask (75 cm<sup>2</sup>) (Nest Biotechnology Co., Ltd, People's Republic of China), exponentially growing A973 cells were irradiated by linear accelerator at a dose rate of 2 Gy/min, with <sup>60</sup>Co as the radioactive source.

### Clonogenic survival

The ability of cells to maintain clonogenic capacity was defined as clonogenic survival. Briefly, samples with or without erlotinib were exposed to radiation doses of 0, 1, 2, 4, 6, 8, and 10 Gy. The cells were fixed with methanol and stained with Giemsa after a 14-day incubation period, and then, the colonies were counted (ie, those containing more than 50 cells). The experiments were repeated three times, and the data were represented as means ± standard deviation. A dose-survival curve was then generated. Survival parameters, such as sublethal damage repair (quasi-threshold dose [Dq]), extrapolation number (N),<sup>12-14</sup> and the cellular radiosensitivity (mean lethal dose [D<sub>0</sub>]), were calculated using a multitarget, single-hit model.<sup>12-14</sup> The cell-survival curves were plotted using Origin<sup>®</sup> 7.5 (OriginLab Corp, Northampton, MA, USA) software, while the

sensitizer enhancement ratios (SERs) were calculated as D<sub>0</sub> values.<sup>12-14</sup>

### Cell apoptosis analysis by flow cytometry


Six groups of cells were used in the experiments: the control (non-treated) group and five experimental groups treated with erlotinib-only, irradiation-only, irradiation after erlotinib, irradiation before erlotinib, or erlotinib concurrent with irradiation. In the groups that received both erlotinib and irradiation, erlotinib was administered 24 hours before irradiation, concurrent with irradiation, and 24 hours after irradiation, respectively. Erlotinib was removed, in all groups, after 12 hours of incubation. Each test was performed three times. The concentration of erlotinib used in the experiments was 50 nM. All combination-treatment groups, as well as the radiation-only group, were exposed to 6 Gy X-rays. After treatment, all the cells were harvested. For the detection of apoptotic cells, the cells were trypsinized and washed with cold phosphate-buffered saline, and then, they were stained with PI and annexin V for 15 minutes in the dark. The cells were then analyzed using fluorescence-activated cell sorting (FACS) on a FACSCalibur machine (BD Biosciences, San Jose, CA, USA).

### Western blot analysis

After irradiation and/or erlotinib treatment, the C-MET-, p-C-MET-, AKT-, and p-AKT-expression levels in the A973 cells were determined by Western blot. The Western blot treatment groups were the same as those used for the FACS. Electrophoresis was performed with polyacrylamide gel under reducing conditions, and then, the proteins were transferred to a nitrocellulose membrane (Bio-Rad Laboratories, Hercules, CA, USA). The blots were incubated with the first antibody at room temperature for 4 hours, followed by incubation with the secondary antibody (horseradish peroxidase labeling goat anti mouse IgG) for 1 hour. The film was then developed and fixed.<sup>15,16</sup> Semiquantification analysis was performed with Image Tool 3.0 grayscale scanning software (UTHSCSA ImageTool 3.0, Department of Dental Diagnostic Science at The University of Texas Health Science Center, San Antonio, TX, USA).

### Statistical analysis

The data were plotted as the means ± standard deviation. Analysis of variance (ANOVA) tables were used for comparisons between multiple groups using SPSS version 17 software (SPSS, Chicago, IL, USA).



**Figure 1** Dose-survival curves of the A973 cells after irradiation with or without erlotinib, based on different administration schedules. **(A)** Radiation groups; **(B)** groups receiving irradiation before erlotinib administration; **(C)** groups receiving simultaneous irradiation and erlotinib administration; and **(D)** groups receiving irradiation after erlotinib administration.

## Results


### Survival curve after different dose irradiation with or without erlotinib

The survival curves of the A973 cells under different treatment regimens are shown in Figure 1. The radiobiological

parameters of the A973 cells were as follows:  $D_0 = 1.12$ ,  $Dq = 0.11$ , and  $N = 1.25$ , in the groups receiving irradiation after administration;  $D_0 = 1.60$ ,  $Dq = 0.16$ , and  $N = 1.26$ , in the groups receiving simultaneous irradiation;  $D_0 = 1.78$ ,  $Dq = 0.34$ , and  $N = 1.55$ , in the groups receiving irradiation before administration; and  $D_0 = 2.45$ ,  $Dq = 1.17$ , and  $N = 3.01$ , in the groups receiving only radiation. The SERs of the groups receiving erlotinib irradiation after administration, simultaneous irradiation and administration, and irradiation before administration were 2.19, 1.53, and 1.38, respectively. The enhanced SERs in the erlotinib-treated cells revealed that the biological effect of irradiation improved significantly when the cells were treated with erlotinib, while the best radiosensitive effect was observed in the group receiving irradiation after erlotinib ( $P < 0.05$ ) compared with the other groups.

### Cell apoptosis

Compared with single-treatment groups, the A973 cells had higher apoptosis rates in all the combination-treatment groups. This effect was the most significant in the group receiving irradiation after administration ( $P < 0.05$ ) compared with



**Figure 2** The apoptosis rates for the A973 cells after different treatment regimens (Q1–Q4 represent different quadrants, with Q4 showing the apoptotic cells). **(A)** Control groups; **(B)** Radiation-only groups; **(C)** Erlotinib-only groups; **(D)** Irradiation after erlotinib administration groups; **(E)** Simultaneous irradiation and erlotinib administration groups; and **(F)** Irradiation before erlotinib administration groups.

**Abbreviations:** PE-A, phycoerythrin antibody; FITC, fluorescein isothiocyanate.

every other group. The percentage of apoptosis indicated that apoptosis might be an important mechanism associated with the radiosensitization effect (Figure 2). The apoptosis rates were as follows:  $0.5\% \pm 0.4\%$  for the control groups;  $21.3\% \pm 3.5\%$ , for the radiation-only groups;  $13.2\% \pm 2.7\%$ , for the erlotinib-only groups; and  $54.7\% \pm 6.3\%$ , for the groups receiving radiation after erlotinib ( $P < 0.05$ ) (group receiving irradiation after erlotinib administration compared with the other groups, based on the ANOVA analysis); were  $37.6\% \pm 4.2\%$ , for the groups receiving radiation and erlotinib simultaneously; and were  $36.8\% \pm 3.9\%$ , for the groups receiving radiation before erlotinib.


### Expression of C-MET, p-C-MET, AKT and p-AKT in the A973 cells after irradiation and/or erlotinib treatment

After treatment with 6 Gy radiation with or without erlotinib, the protein expression of C-MET, p-C-MET, AKT, and p-AKT increased in all of the groups. In all combination groups, the expression of these proteins was the highest in groups receiving irradiation before erlotinib administration and the lowest in groups receiving irradiation after administration (Figure 3). The C-MET and AKT levels were correlated with those of p-C-MET and p-AKT (Figure 3). Furthermore, trends were related to the apoptotic rate in the A973 cells ( $P < 0.05$ ) (based on the correlation test). In grey scanning analysis, the expression of C-MET and p-C-MET was semiquantitated using the C-MET/ $\beta$ -actin ratio, whereas the expression of AKT and p-AKT was semiquantitated using the AKT/ $\beta$ -actin ratio. The relative p-C-MET-expression

levels of the control groups and the groups receiving radiation-only, erlotinib-only, irradiation after erlotinib administration, simultaneous irradiation and erlotinib administration, and irradiation before erlotinib administration were  $17.2\% \pm 8.3\%$ ,  $28.8\% \pm 6.5\%$ ,  $20.0\% \pm 5.1\%$ ,  $40.5\% \pm 6.7\%$ ,  $57.8\% \pm 9.6\%$ , and  $61.8\% \pm 11.8\%$ , respectively. The relative p-AKT-expression levels of the control groups and the groups receiving radiation-only, erlotinib-only, irradiation after erlotinib administration groups, simultaneous irradiation and erlotinib administration, and irradiation before erlotinib administration were  $19.2\% \pm 4.1\%$ ,  $26.2\% \pm 3.8\%$ ,  $22.6\% \pm 4.3\%$ ,  $39.5\% \pm 7.1\%$ ,  $54.9\% \pm 4.3\%$ , and  $60.7\% \pm 7.1\%$ , respectively. The expression levels of C-MET, p-C-MET, AKT and p-AKT in the radiation-only groups and combination groups were significantly higher than in the control groups ( $P < 0.05$ ). The expression levels of C-MET, p-C-MET, AKT, and p-AKT in the groups receiving irradiation before erlotinib administration, simultaneous irradiation concurrent administration, and erlotinib-only administration were higher than the expression levels in the group receiving irradiation after erlotinib administration ( $P < 0.05$ ).

### Discussion

Previous clinical studies assessing the combined treatment of radiation and the erlotinib demonstrated tolerance to toxicity and enhanced efficacy.<sup>17–20</sup> However, basic research in this area is lacking, and the optimal administration schedule for this combined treatment remains undetermined. Moreover, the mechanisms involved in optimizing the effects of such treatment need further research. The results of this study show



**Figure 3** Western blot analysis of C-MET, p-C-MET, AKT, and p-AKT in the A973 cells subjected to 6 Gy irradiation and/or erlotinib-treatment. Left: expressions of C-MET, p-C-MET, AKT, and p-AKT in the A973 cells. Upper right: histogram of C-MET and p-C-MET analysis by grey scanning. Lower right: histogram of AKT and p-AKT analysis by grey scanning. (A) Control groups; (B) Radiation groups; (C) Erlotinib groups; (D) Irradiation after erlotinib administration groups; (E) Simultaneous irradiation and erlotinib administration groups; and (F) Irradiation before erlotinib administration groups.

**Notes:** \* $P < 0.05$  compared with the control groups. # $P < 0.05$  compared with groups (E and F).

**Abbreviations:** p-AKT, phosphorylated AKT; p-C-MET, phosphorylated C-MET.

that the radiosensitizing effects of erlotinib differed when the drug was administered according to different administration schedules, suggesting that these effects might be related to PI3K signal transduction.

Compared with the radiation-only group and the erlotinib-only group, the clonogenic assay showed more desirable results in every combination group. Further, the lethal effect in the group receiving radiation after erlotinib administration was higher than the effects observed in the other combination groups. Our results also showed that radiation after erlotinib administration enhanced the apoptosis rate of the A973 cells more significantly than did the other treatment groups. This result suggests that apoptosis plays an important role when erlotinib is combined with radiation. Increased cell apoptosis was further stimulated by changes in the expression levels of the proteins; these changes were related to PI3K signal transduction. The levels of C-MET, p-C-MET, AKT, and p-AKT proteins were higher in all of the treatment groups and were maximized in those groups receiving irradiation before administration; the lowest levels were observed in the groups receiving irradiation after administration. The trends exhibited by the C-MET and AKT levels mirrored those of the p-C-MET and phosphor-AKT levels, respectively (Figure 3). As such, the expression levels and variation trends of these genes provided the experimental basis for different radiosensitization effects at different administration times.

The reason for the different radiosensitization effects associated with erlotinib may be related to the activation of PI3K signal transduction. More specifically, the cross talk of mitogen-activated protein kinase (MAPK) and PI3K may provide an answer to this question. Both EGFR-RAS-MEK-extracellular signal-regulated kinase (ERK) signal transduction and C-MET-PI3K-AKT signal transduction have roles in the prevention of apoptosis, the regulation of cell cycle progression, and cell proliferation. Further, there are multiple levels of cross talk between the PI3K/AKT and Ras/MAPK signaling pathways.<sup>21–24</sup> When C-MET-PI3K-AKT signal transduction was activated by radiation,<sup>25,26</sup> the high levels of C-MET, p-C-MET, AKT, and p-AKT promoted cell survival and prevented cell death, thereby decreasing the killing effect of the TKIs administered simultaneously with radiation.

In agreement with the results from previous studies<sup>27–29</sup> that assessed the combination of erlotinib and irradiation in tumor treatment, our study also found that erlotinib exerted a radiosensitive effect when it was combined with irradiation. However, we explored the different radiosensitive effects observed when erlotinib was combined with radiation, using

different schedules, as well as the relationship between such treatment and PI3K signal transduction. The results of this study indicate that PI3K signal transduction may play an important role in the effect exerted by the combination of erlotinib and irradiation. This study also provides useful data regarding the regulating effect of TKIs administered simultaneously with radiation, via the PI3K signal transduction inhibitor.

In summary, our study explored optimal administration schedules (irradiation after administration) for the combination of erlotinib and radiation, as well as the relationship between such treatments and PI3K signal transduction. Although this study was preliminary, the radiotherapy effects and gene expression results may be correlated. Nevertheless, many issues remain to be addressed, and we believe that the application of irradiation in combination with EGFR inhibitors has great potential that requires further fundamental research.

## Acknowledgments

This research was funded by the Tianjin Medical University Science and Technology Development Fund (Grant No 2010KY31) and the Tianjin Health Bureau Science and Technology Development Fund (Grant No 2012KZ066).

## Disclosure

The authors report no conflicts of interest in this work.

## References

1. Gschwind A, Fischer OM, Ullrich A. The discovery of receptor tyrosine kinases: targets for cancer therapy. *Nat Rev Cancer*. 2004;4:361–370.
2. Baselga B. Epidermal growth factor receptor pathway inhibitors. *Update Cancer Ther*. 2006;1:299–310.
3. Ciariello F, Tortora G. EGFR Antagonists in Cancer Treatment. *N Engl J Med*. 2008;358(11):1160–1174.
4. Ciariello F, Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. *Clin Cancer Res*. 2001;7(10):2958–2970.
5. Zhu Z. Targeted cancer therapies based on antibodies directed against epidermal growth factor receptor: status and perspectives. *Acta Pharmacol Sin*. 2007;28(9):1476–1493.
6. Harari PM. Epidermal growth factor receptor inhibition strategies in oncology. *Endocr Relat Cancer*. 2004;11(4):689–708.
7. Dassonville O, Bozec A, Fischel JL, Milano G. EGFR targeting therapies: monoclonal antibodies versus tyrosine kinase inhibitors. Similarities and differences. *Crit Rev Oncol Hematol*. 2007;62(1):53–61.
8. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. *JAMA*. 2003;290(16):2149–2158.
9. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. *J Clin Oncol*. 2003;21(12):2237–2246.
10. Liu F, Li Y, Yu Y, Fu S, Li P. Cloning of novel tumor metastasis-related genes from the highly metastatic human lung adenocarcinoma cell line Anip973. *J Genet Genomics*. 2007;34(3):189–195.

11. Li W, Mu D, Song L, et al. Molecular mechanism of silymarin-induced apoptosis in a highly metastatic lung cancer cell line anip973. *Cancer Biother Radiopharm.* 2011;26(3):317–324.
12. Chu PM, Chiou SH, Su TL, et al. Enhancement of radiosensitivity in human glioblastoma cells by the DNA N-mustard alkylating agent BO-1051 through augmented and sustained DNA damage response. *Radiat Oncol.* 2011;6:7.
13. Cariveau MJ, Stackhouse M, Cui XL, et al. Clofarabine acts as radiosensitizer in vitro and in vivo by interfering with DNA damage response. *Int J Radiat Oncol Biol Phys.* 2008;70(1):213–220.
14. Quanz M, Berthault N, Roulin C, et al. Small-molecule drugs mimicking DNA damage: a new strategy for sensitizing tumors to radiotherapy. *Clin Cancer Res.* 2009;15(4):1308–1316.
15. Kim IA, Shin JH, Kim IH, et al. Histone deacetylase inhibitor-mediated radiosensitization of human cancer cells: class differences and the potential influence of p53. *Clin Cancer Res.* 2006;12(3 Pt 1):940–949.
16. Ma PC, Jagadeeswaran R, Jagadeesh S, et al. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. *Cancer Res.* 2005;65(4):1479–1488.
17. Lind JS, Lagerwaard FJ, Smit EF, Senan S. Phase I study of concurrent whole brain radiotherapy and erlotinib for multiple brain metastases from non-small-cell lung cancer. *Int J Radiat Oncol Biol Phys.* 2009;74(5):1391–1396.
18. Stinchcombe TE, Bogart JA. Novel approaches of chemoradiotherapy in unresectable stage IIIA and stage IIIB non-small cell lung cancer. *Oncologist.* 2012;17(5):682–693.
19. Merimsky O, Cheng CK, Au JS, von Pawel J, Reck M. Efficacy and safety of first-line erlotinib in elderly patients with advanced non-small cell lung cancer. *Oncol Rep.* 2012;28(2):721–727.
20. Mehta VK. Radiotherapy and erlotinib combined: review of the preclinical and clinical evidence. *Front Oncol.* 2012;2:31.
21. Maines MD. Biliverdin reductase: PKC interaction at the cross-talk of MAPK and PI3K signaling pathways. *Antioxid Redox Signal.* 2007;9(12):2187–2195.
22. Aksamitiene E, Kiyatkin A, Kholodenko BN. Cross-talk between mitogenic Ras/MAPK and survival PI3K/Akt pathways: a fine balance. *Biochem Soc Trans.* 2012;40(1):139–146.
23. Menges CW, McCance DJ. Constitutive activation of the Raf-MAPK pathway causes negative feedback inhibition of Ras-PI3K-AKT and cellular arrest through the EphA2 receptor. *Oncogene.* 2008;27(20):2934–2940.
24. Jung KH, Park BH, Hong SS. Progress in cancer therapy targeting c-Met signaling pathway. *Arch Pharm Res.* 2012;35(4):595–604.
25. De Bacco F, Luraghi P, Medico E, et al. Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer. *J Natl Cancer Inst.* 2011;103(8):645–661.
26. Liu X, Yao W, Newton RC, Scherle PA. Targeting the c-MET signaling pathway for cancer therapy. *Expert Opin Investig Drugs.* 2008;17(7):997–1011.
27. Stea B, Falsey R, Kislin K. Time and dose-dependent radiosensitization of the glioblastoma multiforme U251 cells by the EGF receptor tyrosine kinase inhibitor ZD1839 ('Iressa'). *Cancer Lett.* 2003;202(1):43–51.
28. Andersson U, Johansson D, Behnam-Motlagh P, Johansson M, Malmer B. Treatment schedule is of importance when gefitinib is combined with irradiation of glioma and endothelial cells in vitro. *Acta Oncol.* 2007;46(7):951–960.
29. Nanda A, Dias-Santagata DC, Stubbs H, et al. Unusual tumor response and toxicity from radiation and concurrent erlotinib for non-small-cell lung cancer. *Clin Lung Cancer.* 2008;9(5):285–287.

## OncoTargets and Therapy

### Publish your work in this journal

OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic agents and protocols on

Submit your manuscript here: <http://www.dovepress.com/oncotargets-and-therapy-journal>

patient perspectives such as quality of life, adherence and satisfaction. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Dovepress